Phaseline

Companies › Aktis Oncology

Aktis Oncology: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[225Ac]Ac-AKY-1189
Nectin-4 targeted alpha-emitting radiopharmaceutical
NECTIN4Phase 1Urothelial Carcinoma BladderDec 2027
[225Ac]Ac-AKY-2519–Phase 1Castration Resistant Metastatic Prostate Cancer; NSCLCDec 2027
[64Cu]Cu-AKY-2519
anti-B7-H3 targeted imaging agent (copper-64 PET tracer)
B7H3Phase 1NSCLCDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07020117[225Ac]Ac-AKY-1189Phase 1Urothelial Carcinoma BladderOncologyDec 2027
NCT07581184[225Ac]Ac-AKY-2519Phase 1Castration Resistant Metastatic Prostate CancerOncologyDec 2027
NCT07887971[225Ac]Ac-AKY-2519Phase 1NSCLCOncologyDec 2028
NCT07887971[64Cu]Cu-AKY-2519Phase 1NSCLCOncologyDec 2028

From the company's SEC filings

Cash and short-term investments of $517m on 2026-06-30; operating cash outflow about $91m a year; runway about 68 months at that burn, to Mar 2032

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NECTIN4 (1) B7H3 (1)

Companies with the same targets

BicycleTx BioNTech SE Mabwell (Shanghai) Bioscience Tianjin ConjuStar Biologics Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.